Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a distigmasterylhemisuccinoyl- glycero-phosphocholine liposome-intercalated amphotericin B

International Journal of Pharmaceutics

Volumn 408, Issue 1-2, 2011, Pages 163-172

  Iman, Maryam ^a   Huang, Zhaohua ^b   Szoka Jr , Francis C ^b   Jaafari, Mahmoud R ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amphotericin B; Cholesterol; Distigmasteryl modified phospholipid; Drug carrier

Indexed keywords

1,2 DISTIGMASTERYLHEMISUCCINOYL SN GLYCERO 3 PHOSPHOCHOLINE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; LIPOSOME; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; COLLOID; CYTOTOXICITY; DRUG FORMULATION; ERYTHROCYTE; FEMALE; IC 50; IN VITRO STUDY; LEISHMANIA MAJOR; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PH; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROMASTIGOTE; TOXICITY TESTING; ZETA POTENTIAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ANTIPROTOZOAL AGENTS; CELL CULTURE TECHNIQUES; CELL LINE; ERYTHROCYTES; FEMALE; INHIBITORY CONCENTRATION 50; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PHOSPHATIDYLCHOLINES; RABBITS; STIGMASTEROL;

EID: 79953251882     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.01.044     Document Type: Article

References (44)

1. Adler-Moore, J., Proffitt, R.T., 2002. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 49 (Suppl. 1), 21-30.
2. Adler-Moore, J.P., Proffitt, R.T., 2008. Amphotericin B lipid preparations: what are the differences? Clin. Microbiol. Infect. 14 (Suppl. 4), 25-36.
3. Andes, D., Safdar, N., Marchillo, K., Conklin, R., 2006. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob. Agents Chemother. 50, 674-684.
4. Bellmann, R., Cleary, J.D., Sterba, J., 2009. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B. Clin. Adv. Hematol. Oncol. 7, 1-8.
5. Boswell, G.W., Buell, D., Bekersky, I., 1998. AmBisome (liposomal amphotericin B): a comparative review. J. Clin. Pharmacol. 38, 583-592.
6. Butler, W.T., Cotlove, E., 1971. Increased permeability of human erythrocytes induced by amphotericin B. J. Infect. Dis. 123, 341-350.
7. Chou, T.C., Talalay, P., 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55.
8. Croft, S.L., 2001. Monitoring drug resistance in leishmaniasis. Trop. Med. Int. Health 6, 899-905.
9. Croft, S.L., Coombs, G.H., 2003. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19, 502-508. (Pubitemid 37329659)
10. Deray, G., 2002. Amphotericin B nephrotoxicity. J. Antimicrob. Chemother. 49 (Suppl. 1), 37-41.
11. Dupont, B., 2002. Overview of the lipid formulations of amphotericin B. J. Antimicrob. Chemother. 49 (Suppl.), 31-36.
12. Dutta, A., Bandyopadhyay, S., Mandal, C., Chatterjee, M., 2005. Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis. Parasitol. Int. 54, 119-122.
13. Ellis, D., 2002. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49 (Suppl. S1), 7-10.
14. Espada, R., Valdespina, S., Alfonso, C., Rivas, G., Ballesteros, M.P., Torrado, J.J., 2008. Effect of aggregation state on the toxicity of different amphotericin B preparations. Int. J. Pharmacol. 361, 64-69.
15. Fahr, A., Van Hoogevest, P., May, S., Bergstrand, N., Leigh, M.L.S., 2005. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur. J. Pharm. Sci. 26, 251-265.
16. Farhoudi-Moghaddam, A.A., Katouli, M., Jafari, A., Bahavar, M.A., Parsi, M., Malekzadeh, F., 1990. Antimicrobial drug resistance and resistance factor transfer among clinical isolates of salmonellae in Iran. Scand. J. Infect. Dis. 22, 197-203.
17. Groll, A.H., Walsh, T.J., 2002. Antifungal chemotherapy: advances and perspectives. Swiss Med. Wkly. 132, 303-311.
18. Guo, L.S., Fielding, R.M., Lasic, D.D., Hamilton, R.L., Mufson, D., 1991. Novel antifungal drug delivery stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharmacol. 75, 45-54.
19. Herbrecht, R., Natarajan-Ame, S., Nivoix, Y., Letscher-Bru, V., 2003. The lipid formulations of amphotericin B. Expert. Opin. Pharmacother. 4, 1277-1287.
20. Huang, Z., Szoka, F.C., 2008. Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties. J. Am. Chem. Soc. 130, 15702-15712.
21. Huang, Z., Jaafari, M.R., Szoka, F.C., 2009. Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery. Angew. Chem. Int. Ed. Engl. 48, 4146-4149.
22. Jaafari, M.R., Bavarsad, N., Bazzaz, B.S., Samiei, A., Soroush, D., Ghorbani, S., Heravi, M.M., Khamesipour, A., 2009. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob. Agents Chemother. 53, 2259-2265.
23. Janoff, A.S., Boni, L.T., Popescu, M.C., Minchey, S.R., Cullis, P.R., Medden, T.D., Tearaschi, T., Gruner, S.M., Shyamsunder, E., Tate, M.W., Mendelsohn, R., Bonner, D., 1998. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. U.S.A. 85, 6122-6126.
24. Jensen, G.M., Skenes, C.R., Bunch, T.H., Weissman, C.A., Amirghahari, N., Satorius, A., Moynihan, K.L., Eley, C.G.S., 1999. Determination of the relative toxicity of amphotericin B formulations: a red blood cell potassium release assay. Drug Deliv. 6, 81-88. (Pubitemid 29279400)
25. Kan, C.C., Yan, J.S., Bittman, R., 1992. Rates of spontaneous exchange of synthetic radiolabeled sterols between lipid vesicles. Biochemistry 31, 1866-1874.
26. Larabi, M., Pages, N., Pons, F., Appel, M., Gulik, A., Schlatter, J., Bouvet, S., Barratt, G., 2004. Study of the toxicity of a new lipid complex formulation of amphotericin B. J. Antimicrob. Chemother. 53, 81-88.
27. Lee, C.C., Gillies, E.R., Fox, M.E., Guillaudeu, S.J., Frechet, J.M., Dy, E.E., Szoka, F.C., 2006. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl. Acad. Sci. U.S.A. 103, 16649-16654.
28. Leenders, A.C., Reiss, P., Portegies, P., Clezy, K., Hop, W.C., Hoy, J., Borleffs, J.C., Allworth, T., Kauffmann, R.H., Jones, P., Kroon, F.P., Verbrugh, H.A., de Marie, S., 1997. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. Aids 11, 1463-1471. (Pubitemid 27421177)
29. Matsumori, N., Yamaji, N., Matsuoka, S., Oishi, T., Murata, M., 2002. Amphotericin B covalent dimers forming sterol-dependent ion-permeable membrane channels. J. Am. Chem. Soc. 124, 4180-4181.
30. Moen, M.D., Lyseng-Williamson, K.A., Scott, L.J., 2009. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs Aging 69, 361-392.
31. Mora, M.P., Tourne-Peteilh, C., Charveron, M., Fabre, B., Milon, A., Muller, I., 1999. Optimisation of plant sterols incorporation in human keratinocyte plasma membrane and modulation of membrane fluidity. Chem. Phys. Lipids 101, 255-265.
32. Olson, J.A., Adler-Moore, J.P., Schwartz, J., Jensen, G.M., Proffitt, R.T., 2006. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob. Agents Chemother. 50, 2122-2131.
33. Phillips, A.J., Sudbery, I., Ramsdale, M., 2003. Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc. Natl. Acad. Sci. U.S.A. 100, 14327-14332.
34. Reed, L.J., Muench, H., 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497.
35. Sriti, J., Talou, T., Wannes, W.A., Cerny, M.,Marzouk, B., 2009. Essential oil, fatty acid and sterol composition of Tunisian coriander fruit different parts. J. Sci. Food Agric. 89, 1659-1664.
36. Szoka, F.C., Milholland, D., Barza, M., 1987. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob. Agents Chemother. 31, 421-429.
37. Takemoto, K., Yamamoto, Y., Ueda, Y., Sumita, Y., Yoshida, K., Niki, Y., 2004. Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. J. Antimicrob. Chemother. 53, 311-317.
38. Torchilin, V.P., 2005. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145-160.
39. Tremblay, C., Barza, M., Fiore, C., Szoka, F., 1984. Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 26, 170-173.
40. Walsh, T.J., Finberg, R.W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R.N., Dummer, S., Schuster, M., Holcenberg, J.S., 1999. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340, 764-771.
41. Walsh, T.J., Goodman, J.L., Pappas, P., Bekersky, I., Buell, D.N., Roden, M., Barrett, J., Anaissie, E.J., 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45, 3487-3496.
42. Wingard, J.R., White, M.H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., 2000. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis. 31, 1155-1163.
43. Yardley, V., Croft, S.L., 1997. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob. Agents Chemother. 41, 752-756.
44. Yardley, V., Croft, S.L., 2000. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents 13, 243-248.